For prostate cancer (PrCa), rare mutations inBRCA2 and BRCA1 give rise to moderately elevated risk,whereas two of ∼100 common, low-penetrance PrCa susceptibilityvariants identified so far by genome-wide association studies implicateRAD51B and RAD23B. The gene discussed is RAD23B; the disease is pure red-cell aplasia.